Cabozantinib

Cabozantinib is a targeted cancer medication used for the treatment of patients with advanced renal cell carcinoma, a type of kidney cancer, and patients with unresectable or metastatic medullary thyroid cancer. It belongs to a class of drugs called kinase inhibitors, which work by blocking the growth and spread of cancer cells.
Renal cell carcinoma accounts for approximately 3% of all adult kidney cancers and is one of the most common types. Cabozantinib is specifically indicated for those patients who have not responded to prior treatment or have experienced progression after receiving other therapies, including anti-angiogenic therapies.
Medullary thyroid cancer is a rare form of the disease, representing about 5% of all thyroid cancers. Cabozantinib has been shown to slow the growth and extend the lives of patients with unresectable or metastatic medullary thyroid cancer.
Cabozantinib is taken as a tablet, typically once a day, and is administered on an ongoing basis until there is evidence of disease progression, unacceptable side effects, or death. As with any medication, the most common side effects are usually manageable and may include fatigue, nausea, constipation, diarrhea, decreased appetite, high blood pressure, and impaired kidney function.
Healthcare professionals should consider the individual patient’s medical history and overall health when prescribing Cabozantinib. While the medication offers significant benefits, patients and doctors must weigh these against the potential risks and side effects. Regular monitoring of the patient’s progress and adverse effects will ensure optimal treatment outcomes and maintain the highest possible quality of life for patients using Cabozantinib.